会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Pyrrolylphenyl-substituted hydroxamic acid derivatives
    • 吡咯基苯基取代的异羟肟酸衍生物
    • US5096919A
    • 1992-03-17
    • US439731
    • 1989-11-20
    • Jan W. F. WasleyKarl O. GelotteHarold Meckler
    • Jan W. F. WasleyKarl O. GelotteHarold Meckler
    • C07D207/32C07D207/325C07D207/327
    • C07D207/325C07D207/327
    • Disclosed are the pyrrolylphenyl-substituted hydroxamic acid derivatives of the formula ##STR1## wherein R represents hydrogen, lower alkyl, halogen or lower alkoxy; R.sub.1 and R.sub.2 independently represent hydrogen, lower alkyl or aryl; Y represents a direct bond, lower alkylene, lower alkenylene, lower alkadienylene, (thio, sulfinyl or sulfonyl)-lower alkylene or oxy-lower alkylene; Z represents ##STR2## wherein R.sub.3 represents hydrogen or acyl; R.sub.4 represents lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, aryl or aryl-lower alkyl; or Z represents ##STR3## wherein R.sub.3 represents hydrogen or acyl; R.sub.5 represents lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, aryl, aryl-lower alkyl, amino or N-(mono- or di-lower alkyl)-amino; R.sub.6 and R.sub.7 represent hydrogen or lower alkyl; and pharmaceutically acceptable salts thereof provided that R.sub.3 represents hydrogen; which are useful as selective lipoxygenase inhibitors, methods for preparation thereof, pharmaceutical compositions comprising said compounds, and a method of inhibiting lipoxygenase and of treating diseases in mammals which are responsive to lipoxygenase inhibition using said compounds and pharmaceutical compositions comprising said compounds of the invention.
    • 公开了式(I)的吡咯基苯基取代的异羟肟酸衍生物,其中R表示氢,低级烷基,卤素或低级烷氧基; R1和R2独立地表示氢,低级烷基或芳基; Y表示直接键,低级亚烷基,低级亚烯基,低级亚烷基亚芳基,(硫代,亚磺酰基或磺酰基) - 低级亚烷基或氧 - 低级亚烷基; Z代表(a)其中R3代表氢或酰基; R 4表示低级烷基,C 3 -C 7 - 环烷基,芳基或芳基 - 低级烷基; 或Z表示(b)其中R3表示氢或酰基; R 5表示低级烷基,C 3 -C 7 - 环烷基,芳基,芳基 - 低级烷基,氨基或N-(单 - 或二 - 低级烷基) - 氨基; R6和R7代表氢或低级烷基; 其药学上可接受的盐,其中R3表示氢; 其可用作选择性脂氧合酶抑制剂,其制备方法,包含所述化合物的药物组合物,以及抑制脂氧合酶的方法,以及使用所述化合物和包含本发明化合物的药物组合物治疗对脂氧合酶抑制作用有抑制作用的哺乳动物疾病的方法。
    • 9. 发明授权
    • Process for production of delta-9-tetrahydrocannabinol
    • 生产delta-9-四氢大麻酚的方法
    • US08106244B2
    • 2012-01-31
    • US13108651
    • 2011-05-16
    • David C. BurdickSteven J. CollierBetina BiolattoHarold Meckler
    • David C. BurdickSteven J. CollierBetina BiolattoHarold Meckler
    • C07C35/18
    • C07C29/00C07C37/16C07C67/343C07C2601/16C07C35/16C07C39/23C07C69/94
    • The present invention relates to a process for preparation of a delta-9-tetrahydrocannabinol compound or derivative thereof involving treating a first intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the delta-9-tetrahydrocannabinol compound or derivative thereof. Another aspect of the present invention relates to a process for preparation of a cannabidiol or cannabidiolate compound involving reacting a first starting compound with a second starting compound in the presence of a metal triflate catalyst, under conditions effective to form the cannabidiol or cannabidiolate compound. The present invention also relates to a compound of the formula: where R8, R9, and R10 are the same or different and independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or halo, with R1, R2, and R3 defined herein.
    • 本发明涉及一种制备δ-9-四氢大麻酚化合物或其衍生物的方法,包括在有效制备δ-9-四氢大麻酚化合物或其衍生物的条件下,用有机铝基路易斯酸催化剂处理第一中间体化合物 。 本发明的另一方面涉及制备大麻二醇或大麻二酸化合物的方法,包括在金属三氟甲磺酸酯催化剂存在下,在有效形成大麻二醇或大麻二醇化合物的条件下使第一起始化合物与第二起始化合物反应。 本发明还涉及下式化合物:其中R 8,R 9和R 10相同或不同且独立地选自H,取代或未取代的烷基,取代或未取代的芳基,取代或未取代的杂芳基,或 卤素,其中R 1,R 2和R 3定义如下。